NEW YORK, April 8, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Celgene Corporation (NASDAQ: CELG), Johnson & Johnson (NYSE:
JNJ), Merck & Co. Inc. (NYSE: MRK), Sanofi (NYSE: SNY), and
UnitedHealth Group, Inc. (NYSE: UNH). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
Celgene Corporation Analyst Notes
On April 1, 2014, Celgene
Corporation (Celgene) announced that it will host a conference call
and live audio webcast on Thursday, April
24, 2014 at 9:00 a.m. ET, to
discuss its Q1 2014 financial and operational results. The Company
informed that the webcast can be accessed on Celgene's website.
According to Zacks Investment Research data, the consensus EPS
estimate for Q1 2014 is $1.43. The
full analyst notes on Celgene Corporation are available to download
free of charge at:
http://www.AnalystsReview.com/04082014/CELG/report.pdf
Johnson & Johnson Analyst Notes
On April 2, 2014, Janssen R&D
Ireland, a part of the Janssen Pharmaceutical Companies of Johnson
& Johnson, announced that two Phase 3 trials are recruiting
patients to evaluate the efficacy and safety of the NS3/4A protease
inhibitor simeprevir in combination with the nucleotide inhibitor
sofosbuvir for the treatment of chronic genotype 1 hepatitis C
virus (HCV) infection in treatment-naïve and treatment-experienced
patients with and without cirrhosis. The first trial, known as
OPTIMIST-1 (Optimal Treatment with a simeprevir and sofosbuvir
Therapy) or TMC435HPC3017, is a Phase 3, multicenter, open-label,
randomized study investigating the efficacy and safety of
simeprevir 150 mg in combination with sofosbuvir 400 mg. And the
second trial, known as OPTIMIST-2 or TMC435HPC3018, is a Phase 3,
multicenter, open-label, single-arm study investigating the
efficacy and safety of simeprevir 150 mg in combination with
sofosbuvir 400 mg. According to the Company, the combination will
be run once daily for 12 weeks in HCV genotype 1 infected patients
with cirrhosis who are HCV treatment naïve or treatment
experienced. The full analyst notes on Johnson & Johnson are
available to download free of charge at:
http://www.AnalystsReview.com/04082014/JNJ/report.pdf
Merck & Co. Inc. Analyst Notes
On April 3, 2014, Merck & Co.
Inc. (Merck) announced that it has been awarded with the ENERGY
STAR 2014 Partner of the Year - Sustained Excellence Award from the
U.S. Environmental Protection Agency (EPA) for its continued
improvement of energy performance and leadership in energy
management in both the pharmaceutical and industrial sectors. Merck
informed that it has been an ENERGY STAR partner since 1995 and
recognized by the EPA for nine consecutive years, twice as Partner
of the Year and now a seventh time for Sustained Excellence. The
Company stated that the award recognizes four Merck manufacturing
sites that have achieved ENERGY STAR rankings in the top 25% of
pharmaceutical plant energy performance nationwide: Arecibo,
Puerto Rico, Cleveland, Tenn., Las Piedras, Puerto Rico; and Elkhorn, Neb. The full analyst notes on Merck
& Co. Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04082014/MRK/report.pdf
Sanofi Analyst Notes
On March 31, 2014, Sanofi
announced the appointment of Anne C.
Beal, M.D., MPH, to the newly created position of Chief
Patient Officer. In his new role, Dr. Beal will be responsible to
further elevate the perspective of the patient within Sanofi so the
company's future healthcare offerings can better incorporate the
unique priorities and needs of patients and caregivers in a variety
of Sanofi activities, ranging from early stage R&D through to
on-market availability of novel healthcare solutions. Commenting on
the appointment, Pascale Witz,
Executive Vice President, Global Divisions and Strategic
Development at Sanofi, said, "Interactions with patients are a
source of strength for the company and Dr. Beal's appointment will
help ensure the patient perspective advances our approach to
meeting the unmet needs of patients." The full analyst notes on
Sanofi are available to download free of charge at:
http://www.AnalystsReview.com/04082014/SNY/report.pdf
UnitedHealth Group, Inc. Analyst Notes
On April 1, 2014, UnitedHealth
Children's Foundation (UHCCF) launched its new "Little Book - Big
Laughs Joke Book" to deliver smiles to children young and old and
raise funds for children with health needs. The Company informed
that the book features more than 600 jokes submitted by kids, for
kids. Jokes include popular and original jokes, funny one-liners,
knock-knock jokes and silly tongue-twisters. The proceeds from the
book will be used to fund future UHCCF grants that help families
pay for children's medical expenses not covered, or not fully
covered, by a commercial health insurance plan. Commenting on the
initiative, UHCCF President Matt
Peterson, said, "At the heart of the book is our desire to
create an uplifting, boredom-busting read to inspire any reader,
whether in a hospital or waiting room, or on a long car ride. The
book's proceeds will help provide child medical grants to families
in need." The full analyst notes on UnitedHealth Group, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/04082014/UNH/report.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya
Ghosh, a CFA charterholder. However, we are only human and
are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Ananya Ghosh, CFA,
has only reviewed the information provided by Analysts Review in
this article or report according to the Procedures outlined by
Analysts Review. Analysts Review is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review